



## Early Phase Clinical Trials: Canada

*Rolling applications*



Funding for clinical trials and clinical trial sub-studies that accelerate the development of therapeutics for neurodegenerative diseases of aging

**Maximum \$1,500,000 over up to 4 years**

### CONTINUING FOR 2020

- Complementary approaches such as diet, physical activity, sleep, nutritional supplements, speech therapy, and cognitive therapy are eligible

### ELIGIBILITY CRITERIA

#### Principal applicant must be:

1. A researcher currently working in Canada at least 30% of the time
2. At or above the level of Assistant Professor or equivalent
3. Affiliated with a Canada Revenue Agency-qualified donee institution located in Canada

#### Project must be:

1. A clinical trial(s) and/or a clinical trial sub-study(s) that accelerates the development of therapeutics for neurodegenerative diseases of aging
2. The development of a therapeutic, tool, and/or complementary approaches

### INSTITUTE DEFINITION OF NEURODEGENERATIVE DISEASES OF AGING

- Alzheimer's disease
- Dementia with Lewy bodies
- Frontotemporal dementia
- Multiple system atrophy
- Parkinson's disease
- Progressive supranuclear palsy
- Vascular contributions to the above
- Prodromes to the above

### APPLICATION PROCESS

1. Review all program information and determine whether your project is in scope
2. Register or sign in to our online grants management system
3. Complete and submit a Letter of Intent (LOI)
  - If selected, applicants will be invited to submit a full Proposal
  - Applicants can expect to receive the outcome of their LOI application within ~2 months of submission
4. Complete and submit a full Proposal (by invite only)

### FOR MORE INFORMATION

[www.westonbraininstitute.ca/early-phase-clinical-trials-canada](http://www.westonbraininstitute.ca/early-phase-clinical-trials-canada)

416-967-7979 | [info@westonbrain.org](mailto:info@westonbrain.org)

